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Synopsis  
Background   
Antimicrobial exposure is associated with increased risk of Clostridium difficile infection (CDI) but 
the impact of prescribing interventions on CDI and other outcomes is less clear.  
Objectives   
To evaluate the effect of an antimicrobial stewardship intervention targeting high risk antimicrobials 
(HRA), implemented in October 2008; to compare the findings to similar studies from a systematic 
review.  
Population and methods   
All patients admitted to Medicine and Surgery in Ninewells Hospital from October 2006 to 
September 2010 were included. Intervention effects on HRA use (dispensed DDD), CDI cases, and 
mortality rates, per 1000 admissions per month, were analysed separately in Medicine and Surgery 
using segmented regression of interrupted time series (ITS) data. Data from comparable published 
studies were re-analysed using the same method.   
Results   
Six months post-intervention, there were relative reductions in HRA use of 33% (95%CI 11 to 56) in  
Medicine and 32% (95%CI 19 to 46) in Surgery. At 12 months, there was an estimated reduction in 
CDI of 7.0 cases/1000 admissions (relative change -24% (95%CI -55 to 6)) in Medicine but no change 
in Surgery (estimated 0.1 fewer cases/1000 admissions (-2% (95%CI -116 to 112)). Mortality reduced 
throughout the study period, unaffected by the intervention. In all six comparable studies, HRA use 
reduced significantly but reductions in CDI rates were only statistically significant in two, and none 
measured mortality. Pre-intervention CDI rates and trends influenced intervention effect.  
  Conclusions  
  Despite large reductions in HRA prescribing and reductions in CDI, demonstrating real-world      
 impact of stewardship interventions remains challenging.  
Introduction  
Clostridium difficile is the leading cause of healthcare-associated infective diarrhoea. C. difficile 
infection (CDI) is potentially life threatening and risk of infection is increased by recent exposure to 
antimicrobials.1 In comparison with other antimicrobials, exposure to cephalosporins and 
clindamycin has been associated with higher risk of CDI in hospitals.2 At population level, 
fluoroquinolone use has been associated with infection by fluoroquinolone-resistant epidemic 
strains and, in the UK, restriction of fluoroquinolones has been associated with reduction in total 
CDI, and in fluoroquinolone-resistant clones from 67% to 3% of all CDI.3   
The direct impact of antimicrobial prescribing interventions on CDI rates is less clearly demonstrated. 
A recent systematic review of interventions to improve antibiotic prescribing for hospital inpatients4 
found no randomised controlled trials (RCTs) and 26 interrupted time series (ITS) studies that 
provided reliable data about the impact of interventions on both prescribing and microbial (CDI or 
resistant Gram-positive and Gram-negative bacteria) outcomes. Nine planned prescribing 
interventions (i.e. not in response to an outbreak) reported heterogeneous effects on CDI rates.5-13   
In 2008, antimicrobial policy changes across Ninewells Hospital, Dundee were initiated, following 
national guidance on restriction of antimicrobials associated with a high risk of CDI (high risk 
antimicrobials [HRA]), designed to reduce prescribing of these agents. The aims of this study were to 
evaluate the impact of these policy changes on HRA prescribing rates, CDI, and mortality in Medical 
and Surgical Wards in Ninewells Hospital, using segmented regression analysis of ITS data, then to 
compare these findings with similar studies from the above systematic review in order to better 
understand variation in the impact of HRA prescribing interventions on CDI.  
Methods  
Setting and population  
Ninewells Hospital is an 855-bed University hospital in the National Health Service (NHS) region of  
Tayside, which had endemic CDI at a rate of 1.5 cases per 1000 acute occupied bed days in 2008. The 
study period was October 2006 to September 2010. We evaluated intervention effects in Medical and 
Surgical wards and included all patients aged ≥ 18 years admitted through the Acute Medical Unit or 
one of six general surgical wards.  Further details of the setting, population and intervention are 
available in Table S1, reported according to the ORION statement recommendations.14  
Intervention  
Antimicrobials defined as HRA were identified from a previous time series analysis of relationship 
between antibiotic use and C. difficile infection rates in Ninewells Hospital.15 In October 2008 the 
NHS Tayside policy for empirical treatment of infection changed to remove cefuroxime for any 
indication, include ceftriaxone only for meningitis, limit fluoroquinolones to a few specific indications 
and reduce use of clarithromycin, clindamycin and co-amoxiclav (Table S2). Cefuroxime was also 
removed from the policy for antibiotic prophylaxis in general surgery (Table S3).  
The policy was implemented via provision of advice from clinical pharmacists at ward level 
supported by departmental presentations by the Chair of the Antimicrobial Management Group and 
Antimicrobial Pharmacist from October to December 2008 (Table S1).  
Outcomes  
Antimicrobial use data were obtained at ward level from the hospital pharmacy computer system 
and summarised as DDD per 1000 admissions per month, separately for Medicine and Surgery.  
CDI data were obtained from the Infection Control Department and summarised as cases per 1000 
admissions per month. The case definition was a patient with diarrhoea and toxin positive stool, 
without toxin positive stool in the previous 90 days. The laboratory diagnostic test changed nine 
months post-intervention but there were no changes to infection control policies over the study 
period (detailed in Table S1).   
We measured 30-day mortality among all patients (deaths within 30 days of admission per 1000 
admissions per month) and among patients who had a blood culture taken (deaths within 30 days of 
having a blood culture taken per 1000 patients with blood culture taken per month) as an indicator 
of sepsis mortality.16 Patient-level hospital admissions and microbiology data were linked to the 
national register of deaths then anonymised by the Health Informatics Centre, University of 
Dundee.17 Mortality was included as a balancing measure due to concerns from clinicians that a 
change in antimicrobial policy may result in inadequate treatment of patients with sepsis. We also 
examined post-operative acute kidney injury as a balancing measure, due to increased use of 
gentamicin as surgical prophylaxis in the new policy, and results are published elsewhere.18  
Statistical analysis  
We used segmented regression analysis of ITS data to estimate intervention effects, using lag terms 
to adjust models for autocorrelation present in residual terms, and using heteroskedastic robust 
standard errors when residual terms were not homoskedastic.19 Effect sizes are the estimated 
absolute and relative changes, with 95% confidence intervals (CI), at six months (prescribing, 
mortality) or 12 months (CDI) post-intervention.  Lower limits of 95%CI for estimated CDI rates that 
were negative were converted to zero. The absolute change is the difference between the modelled 
outcome at the specified post-intervention time point and the model estimate of the last 
preintervention data point, and the relative change is the absolute change as a percentage of the 
model estimate of the last pre-intervention data point. All analyses were carried out in IBM SPSS 
Statistics for Windows, Version 22.0 (Armonk, NY: IBM Corp.).   
Comparison with studies from systematic review  
Of a total 241 studies in the Cochrane systematic review, eight planned ITS studies provided reliable 
prescribing and CDI data, and had monthly or quarterly CDI rates for at least 12 months after the  
prescribing intervention.5, 7-13 Six of these targeted HRA so were comparable with our intervention.5, 
8, 9, 11-13 The remaining two aimed to reduce use of all antibiotics.7, 10 We made descriptive 
comparisons (setting, selection of HRA, etc.) between our study and the six comparable studies, and 
reanalysed prescribing data from five, and CDI data from all six, studies using the same method 
described above to examine variation in effect (one study11 did not present raw prescribing data to 
enable reanalysis). Pre-intervention CDI rates were converted to per 1000 occupied bed days (OBD) 
per month to enable comparison between studies. None of the six studies reported mortality. Due to 
the heterogeneity of study design and outcome measures among the ITS studies, formal meta-
analysis was not applicable. We also reanalysed data from the two studies targeting all antibiotics 
(not just HRA) but these were less directly comparable to our study.   
Ethics  
All patient-identifiable data were anonymised by the Health Informatics Centre (HIC) according to  
Standard Operating Procedures (SOP) which have been agreed with the NHS Tayside Caldicott 
Guardian and East of Scotland Research Ethics Committee. Studies using anonymised data and 
following HIC SOP do not need individual ethics review. All analyses were carried out in an ISO27001 
and Scottish Government accredited data Safe Haven.  
Results  
HRA   
In NHS Tayside use of HRA per 1000 admissions per month in the pre-intervention period varied, 
mainly between 4000–7000 DDD in Medicine versus 2000-4000 DDD in Surgery (Figure 1A and 1B).  
In the pre-intervention period co-amoxiclav accounted for 36% of HRA in Medicine and Surgery.  
Other antimicrobial use, as % of all HRA, in Medicine versus Surgery was: cephalosporin 5 versus  
13%, clarithromycin 32 versus 6%, fluoroquinolone 19 versus 30% and clindamycin 6 versus 7% 
(further details available in Table S4).   
The intervention was associated with progressive reductions in HRA in Medicine (Figure 1A) and 
Surgery (Figure 1B).  At six months post-intervention, use of HRA had reduced by 2094 DDD per 1000 
admissions (relative reduction of 33% (CI 11 to 56%)) in Medicine, and by 1394 DDD per 1000 
admissions (relative reduction of 32% (CI 19 to 46%)) in Surgery (Table 1).   
CDI   
In Medicine there was no significant pre-intervention trend in CDI rates, whereas in Surgery the rate 
was declining by 0.49 cases per 1000 admissions per month (CI 0.29 to 0.69) (Table 1). Immediately 
pre-intervention, there was a higher CDI rate in Medicine than Surgery at 22.0 versus 4.5 per 1000 
admissions (Table 1).   
The intervention was associated with a progressive decline in CDI rates in Medicine (Figure 1C) but 
not in Surgery (Figure 1D).  At 12 months post-intervention CDI in Medicine reduced by 7.0 cases per 
1000 admissions, although this was not quite statistically significant (relative change -24% (95%CI -55 
to 6), Table 1). In Surgery, there was no change associated with the intervention after 12 months 
(model estimate -0.1 CDI cases per 1000 admissions, relative change -2% (95%CI -116 to 112%, Table 
1), reflecting a levelling off from a downward pre-intervention trend (Figure 1D).  
Mortality  
All cause 30-day mortality declined post-intervention in Medicine and Surgery (Figure 2A and 2B, 
Table S5), but there was no statistically significance association with the intervention, with relative 
reductions of 8% (95%CI -24 to 9) in Medicine and 2% (95%CI -35 to 31) in Surgery at six months 
post-intervention. Mortality in patients who had blood cultures taken also declined in both Medicine 
and Surgery (Figures 2C and 2D, Table S5), but again there were no statistically significant changes 
associated with the intervention, with relative changes of -14% (95%CI -39 to 11) and -12% (95%CI 
46 to 23), respectively, at six months post-intervention.  
Comparable studies from systematic review  
There were six studies targeting HRA with adequate (monthly or quarterly for at least 12 months) 
CDI data,5, 8, 9, 11-13 one only included Medicine for the Elderly9 but others included all wards. Five 
were based in the UK but the one US study included six intervention hospitals.11 The definition of 
HRA varied considerably between studies and hospitals and CDI case definitions varied slightly. Not 
all studies reported diagnostic methods or infection control practices (Table 2).  
All interventions were associated with statistically significant reduction in HRA use (Table 1). Changes 
at six months post-intervention could not be estimated for one study,11 but our re-analysis of data 
from the remaining five estimated relative reductions of 27% to 49%, all statistically significant 
(Table 1).  
Immediate pre-intervention CDI rates ranged from 0.6 to 2.7 cases per 1000 OBD per month across 
all eight settings (including in Ninewells Hospital) (Table 2), and pre-intervention CDI rates were 
significantly reducing in three (Table 1). Re-analysis of CDI data from five of the six comparable 
studies estimated relative changes in CDI at 12 months post-intervention that were similar to the 
change in Medicine in Ninewells, but two had much wider confidence intervals: -40% (95%CI -124 to 
43, Dancer8), -48% (95%CI -131 to 35, Talpaert13). Re-analysis of CDI data from the remaining study 
(Ostrowsky11) estimated much smaller relative changes, more similar to Surgery in Ninewells and 
with a similarly low immediate pre-intervention CDI rate (0.6 versus 0.8 per 1000 OBD per month 
(Table 2)).  In only two of eight settings were estimated reductions in CDI at 12 months 
postintervention statistically significant (Fowler9, Price12) and both had relatively flat pre-
intervention trends (although Price has a significant downward trend, the change per month is 
numerically very small meaning the slope is very shallow) (Table 1).   
Studies targeting total antimicrobial use  
Re-analysis of data from one of two studies targeting total antimicrobial use, set in an 861 bed 
tertiary care hospital,7 estimated a 25% (95%CI 19 to 30) relative reduction in antimicrobial use at six 
months post-intervention, and a 24% (95%CI -58 to 10) relative reduction in CDI at 12 months. There 
was no pre-intervention trend in CDI rate (0.02 (95%CI -0.16 to 0.20) cases per OBD per month) and 
a pre-intervention rate of 0.4 cases per 1000 OBD per month. In the other study, set in a 160 bed 
Long Term Care Facility,10 re-analysis of published data estimated a 16% (95%CI 4 to 29) relative 
reduction in antimicrobial use at six months post-intervention, and no change in  in CDI at 12 months 
(relative change 1% (95%CI -73 to 76)). There was no pre-intervention trend in CDI rate (0.02 (95%CI 
-0.01 to  
0.05) cases per OBD per month) and a pre-intervention rate of 1.0 case per 1000 OBD per month.   
Discussion  
In Ninewells Hospital, an intervention to reduce prescribing of antimicrobials associated with high 
risk of CDI resulted in large and significant reductions in prescribing of targeted antimicrobials in 
both clinical settings evaluated. The estimated effects on CDI were inconsistent, and influenced by 
preintervention rates and trends. Reanalysis of prescribing and CDI data from six similar previously 
published studies revealed similar large reductions in prescribing and inconsistent changes in CDI. In 
Ninewells Hospital, there was no evidence that the antimicrobial prescribing intervention was 
associated with any increase in 30-day mortality.  
We analysed the effect of a real-world intervention in two clinical settings within our hospital using a 
statistically robust method for the analysis of quasi-experimental studies. The use of routine data 
enabled complete case identification and complete antimicrobial dispensing data. In addition to 
examining the intended process (HRA prescribing) and outcome (CDI) measures, we also included 
mortality as a balancing measure, which no other similar studies did. A further strength was the 
reanalysis of published data from all similar interventions identified in a recent systematic review4 
using the same methods, allowing direct comparison of effect and helping to explain variation in 
effect size.   
In some segmented regression analyses, the assumption is that pre-intervention trends would have 
continued throughout the study period in the absence of an intervention and the projection of the 
pre-intervention trend used to estimate intervention effects. This can be problematic if the modelled 
projection breaches the limits of measurement, resulting in predicted negative incidence or 
proportions below zero or above 100%. Therefore, we projected the last pre-intervention time point 
forward, assuming a flat post-intervention trend. In Surgery in Ninewells and one comparable study 
(Dancer8) CDI rates were statistically significantly reducing pre-intervention, and extrapolation of 
those trends would have breached zero by 12 months post-intervention, with the result that the 
estimated intervention effect would inevitably have been an increase in CDI.  
In all the analysed interventions there were significant reductions in the use of HRA, but there were 
only significant reductions in CDI in two (Table 1). These results are in marked contrast to a previous 
systematic review, which concluded that Antibiotic Stewardship Programmes (ASP) were associated 
with a consistent, significant reduction in CDI (pooled risk ratio for CDI 0.48, CI 0.38 to 0.62).20 That 
analysis was based on 16 studies, only four of which9, 12, 13, 21 met inclusion criteria for the Cochrane 
systematic review.4 One of those had ITS HRA prescribing data suitable for re-analysis but only 
aggregate CDI data so could not be included in this paper.21 The other 12 studies were either 
uncontrolled before and after studies, which do not meet Cochrane criteria for inclusion in 
systematic reviews,22 or ITS studies with methodological weaknesses. Analysing our Surgery data 
(Figure 1D) as uncontrolled before and after gives a relative risk of CDI post- versus pre-intervention 
of 0.50 (95%CI 0.36 to 0.70) but this difference is clearly attributable to a steady decline in CDI in the 
pre-intervention period rather than an intervention effect (Figure 1D). This highlights a difficulty in 
evaluating the impact of real-world antimicrobial stewardship interventions on downstream 
outcomes because there is often more than one prescribing intervention, healthcare professionals 
change behaviour before/without an intervention, and infection incidence is affected by outbreaks 
and infection control interventions.   
In the eight settings we analysed, the pre-intervention CDI rates were lower for the two 
interventions with smaller estimated intervention effects (Ninewells Surgery, Ostrowsky11) and one 
with very wide confidence limits (Dancer8) (Table 2), and were already declining significantly in two 
of these (Ninewells Surgery, Dancer8) (Table 1). Declining CDI rates are likely multifactorial and, in 
addition to low baseline rates, make demonstrating an additional intervention effect very 
challenging. A Scottish study, more recent than those included in the systematic reviews above, used 
non-linear time series analysis to estimate associations between a change in antimicrobial 
prescribing policy and CDI rates, taking infection control interventions into account, and found that 
compared to predicted rates, CDI prevalence density in hospitals fell by 68% (mean reduction 1·01 
per 1000 occupied bed-days, 0·27– 
1·76) following a change in antimicrobial policy.23 Similarly emphasising the importance of 
antimicrobial stewardship in the control of CDI, a recent study in England, using whole genome 
sequencing of C. difficile, demonstrated that declining CDI rates were largely explained by reductions 
in fluoroquinolone-resistant strains.24 The decline in fluoroquinolone-resistant CDI was significantly 
associated with declining fluoroquinolone prescribing rates rather than infection control.24 Both 
these approaches provide robust evaluations of the impact of stewardship on CDI but the necessary 
data and analytical methods are not available for evaluation of most stewardship interventions.  
The selection of targeted HRA could plausibly influence the effectiveness of prescribing 
interventions. Meta-analyses of case control studies of patient-level CDI risk associated with specific 
antimicrobial exposure have varying results. In healthcare-associated CDI, exposure to 
cephalosporins, particularly third-generation (OR   3.20, 95%CI 1.80 to 5.71), and clindamycin (2.86, 
2.04 to 4.02) had the highest associations, and fluoroquinolones (1.66, 1.17 to 2.35) had weaker 
associations out-with the context of resistant epidemic ribotypes.2 In two meta-analyses of 
community-associated CDI, fluoroquinolone exposure was strongly associated (OR 5.65 (4.38 to  
7.28)25 and 5.50 (4.26 to 7.11)26), as were clindamycin (20.43 (8.50 to 49.09)25 and 16.80 (7.48 to 
37.76)26) and cephalosporins (4.47 (1.60 to 12.50)25 and 5.68 (2.12 to 15.23)26). There were 
similarities in HRA selection across all eight settings we analysed (Table 2), but only Ostrowsky’s 
study included piperacillin-tazobactam, and in that study cephalosporins were only targeted in two 
of six intervention sites and quinolones only in one (Table 1).11 A recent ITS evaluation of multicentre 
antimicrobial stewardship in Australia, where targeted HRA were standardised across five hospitals, 
demonstrated an associated reduction in CDI despite low rates pre-intervention.27 A recent review of 
country-level data on the use of different cephalosporins and CDI rates across Europe, concludes 
that associations with CDI should be considered for individual cephalosporin agents, and argues that 
factors such as cumulative exposure are important,3 which has been reported elsewhere.28, 29 The 
use of certain cephalosporins in a controlled manner may be appropriate to maintain diversity and 
support long term sustainable stewardship.30   
We measured mortality due to concerns raised by clinicians that the change in antimicrobial policy 
could have led to under-treatment of patients with sepsis and we found no evidence of worse 
outcomes with the intervention. There was declining mortality throughout the study period (Figure 
2). Our intervention was co-incident with the start of the Scottish Patient Safety Programme (SPSP)31 
in 2008, which aimed to reduce hospital mortality through early recognition and management of 
deteriorating patients (although the SPSP Sepsis Collaborative only began in 2012). A local sepsis 
improvement initiative in 2009 in Ninewells Hospital was associated with reduced time to first 
antibiotic dose in Medicine and Surgery,16 but not mortality (unpublished data, Marwick and Davey), 
in a smaller study using manually collected patient data. There are limitations in using mortality as a 
stewardship outcome, due to confounding, but it does have value as balancing measure and most 
studies do not report any clinical outcome data.4 A very recent exception is a multicentre 
stewardship study which reported reductions in infection-specific mortality and length of stay, in line 
with similar reductions in all patients, providing reassurance that the intervention did not worsen 
outcome.27 This is consistent with our findings and supports the use of all-cause mortality as an 
outcome in broadly implemented interventions.  
Targeted restriction of HRA is an important stewardship intervention, particularly when CDI rates are 
high and when hyper-virulent strains of CDI are circulating within a population. Robust evaluation of 
the effect of real world stewardship interventions on outcomes other than prescribing remains 
methodologically challenging and worthy of further effort.32 Pre-intervention outcome data should 
be examined before resource-intense interventions and evaluations are undertaken, and all 
evaluations should include balancing measures. Although the included studies focused on restriction 
of HRA in relation to CDI, effective stewardship of all broad spectrum antimicrobials is important to 
reduce adverse effects including healthcare associated infection and the emergence of antimicrobial 
resistance. 
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Table 1: Baseline rates and estimated effect of interventions on HRA prescribing at six months and CDI at 12 months post-intervention from Medicine and 
Surgery in Ninewells Hospital and six comparable studies from a systematic review  
  
Study  
  
HRA data 
included  
High risk antimicrobial (HRA) prescribing rates per month  Clostridium difficile infection (CDI) rates per month  
Units   
Pre-intervention  Change at 6 months  
Units   
Pre-intervention  Change at 12 months  
Trend   Ratea   Absolute   Relative (%)  Trend   Ratea   Absolute   Relative (%)   
   95%CI  95%CI  95%CI  95%CI   95%CI  95%CI  95%CI  95%CI  
Ninewells 
Medicine  
All  
targeted  
DDD/1000  
admissionsb,c  
-70.4  
-107, -33.8  
4186  
2831, 5540  
-2094  
-3488, -699  
-33.3  
-55.5, -11.1  
Cases/1000  
admissionsb  
-0.08  
-0.40, 0.24  
22.0  
13.4, 30.6  
-6.99  
-15.8, 1.84  
-24.1  
-54.5, 6.36  
Ninewells 
Surgery  
All  
targeted  
DDD/1000  
admissionsb  
13.4  
-10.6, 37.4  
2917  
2338, 3497  
-1394  
-1990, -797  
-32.3  
-46.2, -18.5  
Cases/1000 
admissions  
-0.49  
-0.69, -0.29  
4.54  
0d, 9.70  
-0.11  
-5.41, 5.19  
-2.37  
-116.4, 111.6  
Aldeyab 
2012  
All  
targeted  
DDD/100  
OBDc  
0.13  
0.05, 0.21  
22.4  
18.9, 25.9  
-17.3  
-20.9, -13.8  
-43.6  
-52.5, -34.7  
Cases/100 
OBD  
0.001  
-0.002, 0.004  
0.10  
0.04, 0.16  
-0.03  
-0.09, 0.03  
-23.1  
-71.1, 24.9  
Dancer 
2013   CRO  
DDD/1000  
OBDb,c  
-3.35  
-4.90, -1.80  
26.6  
13.4, 39.8  
-25.7  
-39.9, -11.5  
-49.1  
-76.3, -21.9  
Cases/1000 
OBD  
-0.14  
-0.28, -0.006  
1.63  
0d, 3.76  
-1.09  
-3.36, 1.18  
-40.1  
-123.5, 43.4  
Fowler 
2007   AMC, CPS  
Coursese/100 
admissions  
0.54  
0.04, 1.04  
46.8  
37.1, 56.6  
-17.7  
-27.7, -7.59  
-27.4  
-43.0, -11.8  
Casesb  
0.02  
-0.05, 0.09  
3.42  
1.79, 5.05  
-2.86  
-4.55, -1.17  
-45.5  
-72.4, -18.7  
Ostrowsky 
2014  
All  
targeted  
DDD/10,000 
OBD  
-  
  
-  
  
-0.016f  
P=0.015f  
-  
  
Cases/10,00 
0 OBD  
-0.04  
-0.10, 0.02  
5.46  
3.99, 6.93  
-0.48  
-2.00, 1.04   
-8.08  
-33.7, 17.5  
Price 2010  CPS, FQ  DDDc  
-48.0  
-116.2, 20.3  
6375  
5468, 7282  
-2887  
-3844, -1929  
-31.2  
-41.5, -20.8  
Cases/1000 
OBD  
-0.05  
-0.07, -0.02  
1.02  
0.57, 1.47  
-0.60  
-1.08, -0.12  
-37.0  
-66.4, -7.7  
Talpaert 
2011  
AMC, 
CPS, FQ  
DDD/1000  
OBDb  
8.84  
0.08, 17.6  
415.2  
326.8, 503.5  
-151.6  
-247.7, -55.5  
-26.7  
-43.7, -9.8  
Casesb,c  
-0.35  
-2.24, 1.54  
27.6  
0d, 68.2  
-25.5  
-69.3, 18.4  
-48.0  
-130.5, 34.6  
Abbreviations: AMC co-amoxiclav, CPS cephalosporins, CRO ceftriaxone, HRA high risk antimicrobials, FQ fluoroquinolones, OBD occupied bed 
days aImmediate pre-intervention rate = modelled rate at the last pre-intervention time point bModel adjusted for autocorrelation using lag terms 
cModel uses heteroskedastic robust standard errors  
dLower limit of confidence limit was negative so adjusted to zero because a negative CDI rate is not possible 
eCourses = number of seven-day courses  
fFixed effect co-efficient and p-value from segmented regression analysis in original publication, raw data were not available to allow reanalysis   
  
  
  
Table 2: Setting, high risk antimicrobials selected, CDI rates, case definition and changes to diagnosis or infection control policies for Medicine and Surgery 
in Ninewells Hospital and six comparable studies from a systematic review  
Study  Setting  
 
 
 
 
  
Pre- 
intervention 
CDI rate  
(per 1000 
OBD per 
month)  
CDI case definition  
Changes to CDI diagnostic test or 
infection control practices  
Ninewells 
Hospital  
Medicine  CRO, CXM  Yes  Yes  Yes  CIP, MXF  No  2.7*  
Diarrhoea and +ve toxin, 
duplicates removed  
Diagnostic test changed 9 months post 
intervention  
Ninewells 
Hospital  
Surgery  CRO, CXM  Yes  Yes  Yes  CIP, MXF  No  0.8*  
Diarrhoea and +ve toxin, 
duplicates removed  
Diagnostic test changed 9 months post 
intervention  
Aldeyab 
2012  
UK, Whole 
hospital  
CAZ, CRO, 
CTX, CXM  
No  No  No  
CIP, LVX,  
MXF,  
OXF  
No  1.4  
Diarrhoea and +ve toxin, 
duplicates removed  
Screening age (>65 to >12y) and 
cleaning changed at start of 
intervention  
Dancer 
2013   
UK, Whole 
hospital  
CRO  No  No  No  
CIP, LVX,  
MXF,  
OXF  
No  0.8  
HA diarrhoea (48h) and +ve 
test, duplicates removed  
None  
Fowler 
2007   
UK, Medicine 
for the Elderly  
CAZ, CRO, 
CTX, CXM  
Yes  No  No  All  No  2.1*  
Diarrhoea and +ve toxin, 
duplicates not clear  
None  
Ostrowsky 
2014  
USA, Six 
hospitals  
FEP, 2/6 
sites  
No  No  No  
CIP, 1/6 
sites  
Yes, 
6/6 
sites  
0.6  
HA diarrhoea (48h) and +ve 
toxin, duplicates not clear  
Not clear  
Price 2010  
UK, Whole 
hospital  
CAZ, CRO, 
CTX, CXM  
No  Yes  No  
CIP, LVX,  
MXF,  
OXF  
No  1.2  
HA diarrhoea (48h) and +ve 
test, duplicates removed  
Cohorting ward introduced at start of 
intervention  
Talpaert 
2011  
UK, Whole 
hospital  
CAZ, CRO, 
CTX, CXM  
Yes  Yes  No  
CIP, LVX,  
MXF,  
OXF  
No  1.9*  
Diarrhoea and +ve toxin, 
duplicates not clear  
Isolation and cleaning policies changed 
at start of intervention  
*OBD were estimated from data about number of admissions and mean length of stay in the pre-intervention period   
Abbreviations: CAZ ceftazidime, CXM cefuroxime, CIP ciprofloxacin, CRO ceftriaxone, CTX ceftriaxone, FEP cefepime, HA hospital acquired, LVX levofloxacin, MXF 
moxifloxacin, OBD occupied bed days, OXF ofloxacin    
Figures  
Figure 1: Use of high risk antimicrobials (HRA) and C. difficile infection (CDI) rates pre- and post-intervention (introduction of HRA policy) in Medicine 
(1A,1C) and Surgery (1B,1D) in Ninewells Hospital. Solid lines indicate observed values and dashed lines indicate modelled values (modelled lines are 
straight when the model does not require adjustment for autocorrelation). Vertical arrows indicate the intervention time point.  
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Figure 2: 30-day mortality rates among all patients, and among patients who had blood cultures taken, pre- and post-intervention (introduction of HRA 
policy) in Medicine (2A,2C) and Surgery (2B,2D) in Ninewells Hospital. Solid lines indicate observed values and dashed lines indicate modelled values 
(modelled lines are straight when the model does not require adjustment for autocorrelation). Vertical arrows indicate the intervention time point.  
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Table S1: Overview of study design: setting, population, nature and timing of antibiotic 
prescribing and infection control interventions 
Setting: Nine adult medical wards and six adult surgical wards in a 855 bed University hospital 
Dates: October 2006 to September 2010 
Population characteristics:   
Medical:  29,651 consecutive admissions through the Acute Medical Admissions Unit.  
Surgical: 30,562 consecutive admissions to six general surgical wards (abdominal, urological and vascular surgery). 
Endemic C. difficile infection at an average of 1.5 cases per 1000 acute occupied bed days in the pre-intervention period with no 
significant increase in the seven years from 2000-2006.  
Few inter-hospital transfers from two other hospitals in Tayside with no change during the study period. No inter-hospital transfers 
from other regions. 
 Antibiotic policy Audit and Feedback Infection Control Policy 
Phase 1: 
24 months 
(1 October 
2006 to 30 
September 
2008) 
Policy for use of ALERT antibiotics 
introduced in August 2000, implemented 
by advice from clinical pharmacists.  
(i) Carbapenems: imipenem and 
meropenem 
(ii) Glycopeptides: teicoplanin and 
vancomycin 
(iii) Intravenous (iv) amphotericin 
(iv) Ciprofloxacin (iv) 
(v) Linezolid (iv and oral) 
(vi) Piperacillin–tazobactam (Tazocin) 
(vii) Third-generation cephalosporins: 
ceftriaxone, cefotaxime and ceftazidime 
Quarterly reports on ALERT 
antibiotic use by Clinical 
Group introduced in 2003. 
Reports expanded to include 
all antibiotics in April 2007. 
Quarterly reports on C 
difficile infections to clinical 
groups throughout Phase 1. 
Quarterly Infection Control 
reports with balanced 
scorecard to Clinical Groups 
and NHS Tayside Board from 
Policy for isolation of any patient 
with diarrhoea and any patient with 
confirmed C difficile infection in 
single rooms with aprons and gloves 
worn for contact throughout Phase 1. 
Weekly hand hygiene audits by staff 
in study wards from 2005. 
Supplemented with bi-monthly audits 
by Infection Control practitioners as 
part of the National Hand Hygiene 
Campaign from 2007. Annual 
environmental infection control audits 
by Infection Control practitioners 
Phase 2: 
24 months 
(1 October 
2008 to 
30th 
September 
2010) 
ALERT antibiotic policy remained in 
place. 
Narrow spectrum antibiotic policy 
reducing use of cephalosporins, co-
amoxiclav and quinolones. Cefuroxime 
and moxifloxacin restricted by removal 
from stock in wards and operating theatres. 
Policy implemented from October 2008 by 
advice from clinical pharmacists supported 
by departmental presentations by Chair of 
the Antimicrobial Management Group and 
Antimicrobial Pharmacist from October to 
December 2008 
Quarterly reports on antibiotic 
use adapted to show use of 
restricted and recommended 
antibiotics. Compliance with 
the new antibiotic policy was 
also included in quarterly 
Infection Control reports and 
balanced scorecards to 
Clinical Groups and Clinical 
Governance Committees. 
As Phase 1, no change in frequency 
of hand hygiene or other audits. NHS 
Tayside participated in the second 
phase of the Safer Patients Initiative 
and in the Scottish Patient Safety 
Programe and hand hygiene measures 
were in place throughout the pre- and 
post-intervention phases. 
ALERT antibiotic policy (Phase 1): ALERT antibiotics limited to defined indications documented in the Antibiotic Policy. 
Pharmacists reviewed patients receiving ALERT antibiotics and recommended change 
Antibiotic Man policy (Phase 2): designed to eliminate use of cefuroxime or moxifloxacin and reduce use of ceftriaxone, co-
amoxiclav, ciprofloxacin, clarithromycin and clindamycin. ALERT antibiotic policy for use of ceftazidime, piperacillin-tazobactam 
or meropenem unchanged from Phase 1. The new policy promoted use of amoxicillin, co-trimoxazole, doxycycline and gentamicin 
for treatment (Table S2) and co-amoxyclav.  
Intervention components: antibiotic policy available online (Tables S2 and S3), educational meetings, audit of drug supply to 
wards with quarterly feedback, restriction by removal (cefuroxime and moxifloxacin). 
Isolation details (both phases): all participating wards have six single rooms. All other beds configured in six bedded bays. Wall 
mounted liquid soap and alcohol handrub dispenser and sink in each bay and side room with additional alcohol handrub dispensers 
for staff on trolleys. 
Definition of C difficile infection (both phases): an episode of diarrhoea with a sample that was positive for toxin. Mandatory 
testing for C difficile in stool samples from all patients aged 65 or over introduced in Scotland in October 2007. Culture not 
routinely performed. Routine testing was by the automated EIA system VIDAS. As of 28 January 2009 all Vidas equivocal results 
had a Quik Chek Complete carried out in addition to the Vidas test and results interpreted as below: 
VIDAS  Quik Chek 
GDH  
Quik Chek 
TOX  
REPORT  
Equivocal  Positive  Negative  Cl. difficile toxin test indeterminate REP  
Equivocal  Positive  Positive  Cl. difficile toxin detected  
Equivocal  Negative  Negative  Cl. difficile toxin not detected  
Equivocal  Negative  Positive  Cl. difficile toxin test indeterminate REP  
 
 
Table S2: NHS Tayside Antibiotic Man introduced in October 2008 
 
Table S3: NHS Tayside policy for antibiotic prophylaxis in general surgery 
 
 
ANTIBIOTIC PROPHYLAXIS IN GENERAL SURGERY 
  
The aim of surgical prophylaxis is to reduce rates of surgical site and healthcare-associated infections and so reduce surgical morbidity and 
mortality.  There is however growing evidence that aspects of prescribing practice may themselves be associated with health-care associated 
infections, notably Clostridium difficile infection (CDI).  The Scottish Antimicrobial Prescribing Group (SAPG), along with the Scottish 
Government, is monitoring surgical prophylaxis in order to reduce the rates of CDI and resistance.   
SIGN guideline 104 (published in 2008 and updated 2014) has outlined which surgical procedures require prophylactic antibiotics based on a 
review of the available evidence.  Principles of prophylaxis have also been outlined, including timing and duration of antibiotic administration.  
In conjunction with the surgical specialties within NHS Tayside the Antimicrobial Management Group has undertaken to review local 
prophylaxis policy and to formulate a uniform policy.    
  
 Principles of Antibiotic Prophylaxis Policy  
  
1. Indication for prophylaxis should comply with SIGN 104 guideline i.e. when ‘highly recommended’, ‘recommended’ or 
‘considered’ within guideline.  
2. Timing of antibiotic(s):  
 Optimum timing is intravenous dose given or infusion completed 60 minutes prior to skin incision   
 Sub-optimal if >1 hour prior to skin incision or post-skin incision  
3. Recording of antibiotic prescription in ‘once only’ section of medicine chart to avoid multiple dosing  
4. Frequency of administration should be single dose only unless:  
 1.5 litres intra-operative blood loss - re-dose following fluid replacement  (see administration 
guidance table)  
 operation prolonged (see administration guidance table)  
 specifically stated in following guidelines  
5. Documentation in medical notes of reason for antibiotic administration beyond single dose or state intention for antibiotic treatment 
course  
6. Choice of agent should:  
Written by:  NHS Tayside Antimicrobial Management Group/Surgical Directorate 
Date:  2008  
 
 Avoid cephalosporins, clindamycin, quinolones and co-amoxiclav wherever possible  
 Use narrow spectrum agents when possible to minimise impact on resistance and CDI  
 Take into account local resistance patterns  
 Provision of alternatives for beta-lactam allergy  
7. De-colonisation therapy/MRSA positive  
 If a patient is identified as MRSA positive from screening swabs within 3 weeks of anticipated date of elective surgery then a 
decolonisation program should be started as per MRSA protocol. The decolonisation regimen should also be restarted the day they 
come into hospital for 5 days to reduce the microbial load perioperatively. For surgical prophylaxis for primary operations 
vancomycin infusion should be added to the regime recommended in the table below (except for breast surgery where it would be 
used as a replacement). If they have an MRSA infection prior to elective surgery the approach is the same as for any other infection.  
8. Complex individual prophylaxis issues should be discussed with Microbiology or Infectious Diseases pre-operatively and recorded 
in medical notes 9.  Compliance with local policy is required and monitored by NHS Tayside. Any deviation from policy must be 
recorded in the appropriate medical records.  
  
For details of antibiotic administration see last page.  
 
Type of Surgery  Procedure  SIGN 104  
Recommendation  
Antibiotic(s)  Comments  
(if patient is MRSA positive refer to section 7 above)  
Breast Surgery  Breast Cancer Surgery  
Breast Reshaping Procedures  
Locally ‘Recommended’  Flucloxacillin IV  If penicillin allergic use Clindamycin IV   
  
Breast Surgery with Implant 
(reconstructive or aesthetic)  
‘Recommended’  Flucloxacillin IV  If penicillin allergic use Clindamycin IV   
Vascular Surgery        See separate Vascular Unit Policy  
Head and Neck Surgery  Thyroidectomy  ‘Not recommended’    Clean, benign surgery  
Upper Gastro-intestinal  Oesophageal Surgery  
Stomach and Duodenal Surgery  
Gastric Bypass Surgery  
Small Intestine Surgery  
‘Recommended’  Gentamicin IV   
+   
Metronidazole IV   
If patient is receiving dialysis, an eGFR <30ml/min, Cr >350 or 
acute kidney injury consider using co-amoxiclav instead.  If 
patient has any renal issues, as above, and penicillin allergy please 
seek ID or Microbiology advice on choice of antibiotic prophylaxis.  
Hepatobiliary  Bile Duct Surgery  
Pancreatic Surgery  
Liver Surgery  
‘Recommended’  Gentamicin IV   
+   
Metronidazole IV   
If patient is receiving dialysis, has an eGFR <30ml/min, Cr >350 
or acute kidney injury consider using co-amoxiclav instead.  If 
patient  has  
any renal issues, as above, and penicillin allergy please seek ID or  
Gall Bladder Surgery (open)  Microbiology advice on choice of antibiotic prophylaxis.  
Gall Bladder Surgery (laparoscopic)  ‘Not recommended’ but 
should be ‘considered’ in 
‘high risk’ patients  
If required use:  
Gentamicin IV   
+   
Metronidazole IV   
‘High risk’: intraoperative cholangiogram, bile spillage, 
conversion to laparotomy, acute cholecystitis/pancreatitis, 
jaundice, pregnancy, immunosuppression, insertion of 
prosthetic devices.  
If patient is receiving dialysis, has an eGFR <30ml/min, Cr >350 
or acute kidney injury consider using co-amoxiclav instead.  
If patient has any renal issues, as above, and penicillin allergy please 
seek ID or Microbiology advice on choice of antibiotic prophylaxis.  
Lower Gastro-intestinal  Appendectomy  
Colorectal Surgery  
‘Highly recommended’  Gentamicin IV   
+   
Metronidazole IV   
If patient is receiving dialysis, has an eGFR <30ml/min, Cr >350 
or acute kidney injury consider using co-amoxiclav instead.  
If patient has any renal issues, as above, and penicillin allergy please 
seek ID or Microbiology advice on choice of antibiotic prophylaxis.  
Abdomen  Hernia repair-groin  
  Inguinal/femoral with or  
without mesh  
 Laparoscopic with or 
without mesh  
Hernia repair (incisional with or 
without mesh)  
‘Not recommended’      
Open/laparoscopic surgery with 
mesh  (e.g. gastric band or 
rectoplexy)  
‘Not recommended’  but 
should be ‘considered’ in 
‘high risk’ patients  
If required use:  
Gentamicin IV   
+   
Metronidazole IV  
‘High risk’: pregnancy, immunosuppression, insertion of prosthetic 
devices. If patient is receiving dialysis, has an eGFR <30ml/min, 
Cr >350 or acute kidney injury consider using co-amoxiclav 
instead.  
If patient has any renal issues, as above, and penicillin allergy please 
seek ID or Microbiology advice on choice of antibiotic prophylaxis.  
Diagnostic endoscopic procedures  ‘Not recommended’      
Therapeutic endoscopic procedures 
(ERCP)  
‘Not recommended’  but 
should be ‘considered’ in 
‘high risk’ patients  
If required use:  
Gentamicin IV   
+   
Metronidazole IV   
‘High risk’: pregnancy, immunosuppression, insertion of prosthetic 
devices. If patient is receiving dialysis, has an eGFR <30ml/min, 
Cr >350 or acute kidney injury consider using co-amoxiclav 
instead.  
If patient has any renal issues, as above, and penicillin allergy please 
seek ID or Microbiology advice on choice of antibiotic prophylaxis.  
  
  
Spleen  Splenectomy  ‘Not recommended’        
  
  
  
IV Antibiotic Administration Guidance:  
  
Antibiotic  Dose  Administration  Prolonged surgery  >1.5L blood loss redose  
after fluid replacement  
Metronidazole  BMI <30      500mg  
  BMI ≥30       1g  
  
Infusion over 20 minutes  
Infusion over 40 minutes (at least 
500mg to be infused before knife to 
skin)  
Redose 500mg after 8 hours  500mg  
Gentamicin  4mg/kg  
Use ideal body weight (IBW) if >20% overweight  
IBW = (males: 50kg, females: 45.5kg) +0.9kg for every cm 
>150cm  
Bolus over at least 5 mins or 
infusion  
Can also be added to metronidazole 
infusion bag  
Redosing not required  Redosing not required  
Flucloxacillin  1g  Bolus over 3-5 minutes  Redose 500mg after 4 hours  500mg  
Clindamycin  600mg  Infusion over 20 minutes  Redose 300mg after 4 hours  300mg  
Co-amoxiclav  1.2g  Bolus over 3-5 minutes  Redose 600mg after 4 hours  600mg  
Vancomycin  1g  Infusion over 100-120 
minutes in 250ml sodium 
chloride 0.9%  
Redose after 12 hours  500mg  
  
 
 
Table S4: Use of HRA in Medicine and Surgery in Ninewells Hospital pre- and post-intervention in DDD per 1000 admissions per month.  
 
Medicine 
    
Surgery 
    
Drug 
Pre-
intervention % total 
Post-
intervention % total 
Difference 
(post-pre) 
Pre-
intervention % total 
Post-
intervention % total 
Difference 
(post-pre) 
Ceftriaxone 202 4.1% 129 9.1% -73 16 0.6% 15 1.8% -104 
Cefuroxime 62 1.2% 
2 (0 from 13 
months) 0.2% -60 315 12.3% 
19 (0 from 13 
months) 2.2% -296 
Ciprofloxacin 634 12.7% 355 25.0% -279 750 29.2% 273 32.5% -477 
Moxifloxacin 309 6.2% 
5 (0 from 10 
months) 0.3% -304 19 0.7% 0 0.0% -19 
Clarithromycin 1610 32.3% 356 25.0% -1254 162 6.3% 45 5.4% -117 
Clindamycin 311 6.2% 215 15.1% -96 176 6.8% 90 10.8% -85 
Co-amoxiclav 1773 35.6% 270 19.0% -1503 916 35.7% 267 31.8% -649 
Total 4979 
 
1421 
 
-3558 2354 
 
710 
 
-1644 
Ceftazidime was not targeted but was already part of the ALERT antibiotic policy. In Medicine ceftazidime use was 78 DDD per 1000 
admissions per month in the pre-intervention period and increased to 89 in the post-intervention period (difference +11, compared with much 
larger reductions in all targeted antimicrobials in Table). Ceftazidime was not used at all in Surgery pre- or post-intervention. 
 
Table S5: Mortality among all admissions and among patients who had blood cultures taken, in Medicine and Surgery in Ninewells Hospital 
Group Units (per month) Pre-intervention trend Baseline rate* Absolute change at 6 months Relative change at 6 months 
Ninewells Medicine 
Deaths within 30 days per 1000 
admissions 
0.6 71.2 
-5.7 
(-18.7 to 7.2) 
-7.5% 
(-24.4 to 9.4) 
Ninewells Surgery 0.2 30.1 
-0.6 
(-10.8 to 9.7) 
-1.9% 
(-35.2% to 31.4%) 
Ninewells Medicine 
Blood cultures Deaths within 30 days per 1000 
blood culture patients 
2.0 144.4 
-23.5 
(-65.5 to 18.5) 
-14.0% 
(-39.0% to 11.0%) 
Ninewells Surgery 
Blood cultures 
0.5 97.8 
-12.9 i, ii 
(-50.9 to 25.1) 
-11.7% 
(-46.0 to 22.7) 
i Model has been adjusted for autocorrelation using lag terms, ii Model has heteroskedastic robust SE terms 
